PAD inhibitors have already been successfully employed in preclinical and in vitro studies for various inflammatory conditions, such as arthritis, colitis, and sepsis, showing a good safety profile (Chumanevich et al., 2011; Willis et al., 2011). The gene discussed is PADI4; the disease is Sepsis.